Woodline Partners’s Nurix Therapeutics NRIX Stock Holding History

Woodline Partners’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3M	Hold	925,444	–	–	0.05%	420
2025 Q4	$17.6M	Buy	925,444 +848,900	+1,109%	+$12.2M	0.07%	340
2025 Q3	$707K	Sell	76,544 -23,727	-24%	-$246K	﹤0.01%	821
2025 Q2	$1.14M	Buy	100,271 +67	+0.1%	+$724	0.01%	791
2025 Q1	$1.19M	Sell	100,204 -238,258	-70%	-$3.98M	0.01%	746
2024 Q4	$6.38M	Buy	338,462 +1,583	+0.5%	+$36.3K	0.04%	436
2024 Q3	$7.57M	Buy	336,879 +34,992	+12%	+$793K	0.06%	337
2024 Q2	$6.3M	Buy	+301,887	New	+$4.7M	0.06%	314
2022 Q2	–	Sell	-219,281	Closed	-$3.07M	–	859
2022 Q1	$3.07M	Sell	219,281 -373,660	-63%	-$6.63M	0.05%	309
2021 Q4	$17.2M	Buy	592,941 +455,540	+332%	+$13.8M	0.25%	120
2021 Q3	$4.12M	Buy	+137,401	New	+$4.24M	0.07%	285
2021 Q1	–	Sell	-161,211	Closed	-$5.3M	–	459
2020 Q4	$5.3M	Buy	161,211 +17,124	+12%	+$567K	0.14%	154
2020 Q3	$5.03M	Buy	+144,087	New	+$3.63M	0.16%	128

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Woodline Partners's NRIX Position: Q1 2026 in Review

Woodline Partners held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 925,444 shares worth $14.3M. The position accounts for 0.05% of the portfolio, ranked #420.

Woodline Partners first reported a position in NRIX in Q3 2020 and has held it in 13 quarters since. The position peaked at $17.6M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Woodline Partners held 925,444 shares of Nurix Therapeutics worth $14.3M as of Q1 2026.
Woodline Partners left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.05% of Woodline Partners's portfolio in Q1 2026, its #420 holding.
Woodline Partners first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 13 quarters since.
Woodline Partners's Nurix Therapeutics position peaked at $17.6M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.